Article
Targeted Therapies: The Rare Cancer Paradigm
28 Oct 2009
Abstract excerpt
This review analyzes the state of the art of targeted therapies for several tumors, starting from the paradigmatic example of Imatinib treatment in chronic myelogenous leukemia (CML). We discuss how rare tumors can be models for various mechanisms of receptor tyrosine kinase (RTK) activation, and provide the opportunity to develop new therapies also for more common cancer types. We discuss the activation of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
